Group 1 - The core point of the article is that Watson Bio and its subsidiaries have received approval from the National Medical Products Administration for clinical trials of a varicella live attenuated vaccine [1] Group 2 - The clinical trial aims to prevent chickenpox [1] - The companies involved in the development and application for the clinical trial include Yunnan Vaccine Laboratory Co., Ltd., Beijing Watson Innovative Biotechnology Co., Ltd., and Yuxi Watson Biotechnology Co., Ltd. [1]

Core Viewpoint - Chengdu XianDao (688222.SH) announced that its subsidiary, XianYuan, has established an innovative technology system focusing on chronic disease treatment, particularly targeting hypertension, hyperlipidemia, and high body fat [1] Group 1: Company Developments - XianYuan has developed novel technologies including small nucleic acid modification technology, extrahepatic delivery technology, and single-molecule dual-target regulation technology [1] - The ultra-long-acting antihypertensive drug LDR2402 targeting the AGT site has entered Phase II clinical trials, with the first subject already dosed [1] - The clinical trial application (IND) for the small nucleic acid new drug LDR2515 injection (targeting INHBE) for obesity treatment has recently received implied approval from the China National Medical Products Administration (CDE) [1] Group 2: Financing and Shareholding - XianYuan is a subsidiary and affiliated party of Chengdu XianDao, with a registered capital of 17.24 million yuan [1] - Chengdu XianDao plans to subscribe to an additional registered capital of 24 million yuan at a pre-investment valuation of 450 million yuan, increasing its shareholding in XianYuan from 23.20% [1] - The lead investor in this financing round is Chengdu Angel DaoYuan GuoSheng Medical Health Venture Capital Partnership (Limited Partnership), with other investors including affiliated parties Cao Jiaming and Huabo Medical [1]

Investment Rating - The report assigns a "Buy" rating to the company, believing its current stock price is undervalued due to a high implied weighted average cost of capital of 12% [1] Core Insights - The report highlights that the company, Innovent Biologics, is expected to maintain its leading position in the Chinese biotechnology sector, driven by a strong pipeline of novel molecules targeting next-generation immuno-oncology [1] - Encouraging preliminary data has been obtained for IBI363, a PD-1/IL-2α bispecific antibody, which exhibits differentiated drug characteristics in immunotherapy and cold tumors [1] - The company's robust commercialization capabilities and deep collaboration with global partners, particularly Eli Lilly, are also emphasized as key strengths [1] Summary by Relevant Sections - **Investment Rating**: "Buy" rating with a target price of HKD 102.85 based on risk-adjusted discounted cash flow [1] - **Market Position**: Innovent Biologics is positioned as a leader in the Chinese biotech field, supported by a strong pipeline and strategic partnerships [1] - **Product Development**: IBI363 shows promising initial results, indicating potential for differentiation in the competitive landscape of immunotherapy [1] - **Commercialization Strength**: The company’s strong commercial capabilities and partnerships enhance its market prospects [1]

Core Viewpoint - Morgan Stanley reports that Innovent Biologics (01801) has entered into a strategic partnership with Eli Lilly (LLY.US) to jointly develop novel biologics focused on oncology and immunology globally [1] Group 1: Company Overview - Innovent Biologics is reaffirmed as a top pick among Chinese biotech companies covered by Morgan Stanley, with an "Overweight" rating and a target price of HKD 111 [1] - The collaboration is seen as a positive surprise and marks a significant milestone in Innovent's journey towards becoming a global biopharmaceutical company, highlighting the strength of its R&D platform [1] Group 2: Management and Strategy - During a conference call, Innovent's management reiterated its long-term vision, primarily supported by a dual-engine growth strategy in the areas of generic biologics and oncology drugs [1] - Morgan Stanley continues to be impressed by Innovent's execution capabilities in its commercial and R&D product lines, as well as its strong business development abilities [1]

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. (stock code: 688575) has received a notice from the China Securities Regulatory Commission (CSRC) regarding a formal investigation for suspected violations of information disclosure laws [1] Group 1: Investigation Details - The CSRC has decided to initiate a formal investigation against the company due to alleged violations of the Securities Law of the People's Republic of China and the Administrative Penalty Law [1] - The company will actively cooperate with the CSRC during the investigation and will adhere to regulatory disclosure obligations [1] - As of the announcement date, the company has not received a final conclusion from the CSRC regarding the investigation [1] Group 2: Investor Compensation - Investors who purchased Yahui Long shares between the listing date and February 7, 2026, and either held or sold the shares after February 8, 2026, may be eligible for compensation [2] - The initial compensation conditions are subject to confirmation by the court's effective judgment [2] - Required documentation for compensation includes original transaction statements, copies of investor identification, and confirmation of securities account information from the brokerage [3]

Core Viewpoint - The announcement highlights the successful administration of the first patient in a Phase Ib/II clinical trial for the treatment of recurrent or metastatic triple-negative breast cancer (TNBC) using the bispecific antibody, Opalizumab (LBL-024), which targets PD-L1 and 4-1BB [1] Group 1: Clinical Trial and Drug Development - The Phase Ib/II clinical trial is an open-label, multicenter study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital, aiming to evaluate the efficacy and safety of Opalizumab alone or in combination with albumin-bound paclitaxel for TNBC patients [1] - Opalizumab is the first bispecific antibody targeting both PD-L1 and 4-1BB, showing potential as a leading therapy for advanced pulmonary neuroendocrine carcinoma and demonstrating promising clinical activity in various indications [1][2] - The drug has received several regulatory designations, including Breakthrough Therapy Designation (BTD) from the NMPA in October 2024 and Orphan Drug Designation from the FDA in November 2024 for neuroendocrine carcinoma [2] Group 2: Market Need and Cancer Statistics - Cancer remains a leading cause of morbidity and mortality globally, with breast cancer being the second most common cancer, accounting for approximately 2.3 million new cases annually [3] - In China, the incidence of breast cancer continues to rise, with an estimated 360,000 new cases and 75,000 deaths each year, highlighting the urgent need for effective treatments, particularly for TNBC, which represents 15% to 20% of all breast cancer cases [3] - TNBC is characterized by high malignancy, recurrence rates, and poor prognosis, indicating a significant unmet clinical need for more effective treatment options beyond standard chemotherapy [3]

Core Viewpoint - The announcement highlights the successful administration of the drug Opalizumab (PD-L1/4-1BB bispecific antibody, LBL-024) to the first patient in a Phase Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [1] Group 1: Clinical Trial Details - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital [1] - The trial is being conducted simultaneously across multiple hospitals nationwide [1] - The objective of the trial is to evaluate the efficacy and safety of Opalizumab administered alone or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]

Group 1: Company Ratings and Collaborations - Haitong International maintains a "Buy" rating for Innovent Biologics (01801.HK), highlighting a new global strategic collaboration with Eli Lilly, which includes a $350 million upfront payment and up to $8.5 billion in milestone payments, focusing on innovative drug development in oncology and immunology [1] - CITIC Securities also maintains a "Buy" rating for Innovent Biologics, emphasizing the trust from multinational corporations in its innovative capabilities and projecting a 45% increase in product revenue by 2025, alongside the commercialization of 17 drugs and advancements in multiple Phase III pipelines [2] - Yuanta Securities maintains a "Buy" rating for Innovent Biologics, noting the new "China PoC + global development" model that enhances its R&D capabilities and forecasts product revenue to reach 11.9 billion yuan in 2025, a 45% year-on-year increase [3] Group 2: Other Company Ratings - CICC maintains an "Outperform" rating for Guoquan (02517.HK) with a target price of 4.90 HKD, citing steady same-store growth in the second half of 2025 and an accelerated store opening pace in 2026, with over half of its market share in rural areas [4] - CICC also maintains an "Outperform" rating for Kelun-Biotech (06990.HK) with a target price of 550 HKD, highlighting the approval of TROP2 ADC for new indications and significant commercial potential expected in 2026 [5] - Guohai Securities maintains a "Buy" rating for Sihuan Pharmaceutical (00460.HK), forecasting a return to profitability in the first half of 2025, with a significant revenue increase in its medical aesthetics segment [6] - Everbright Securities initiates coverage on Yujian Xiaomian (02408.HK) with an "Accumulate" rating and a target price of 4.90 HKD, noting its leading position in the Sichuan-Chongqing flavor noodle market and strong growth potential through market penetration [7] - Guoxin Securities initiates coverage on Power Development (01277.HK) with an "Outperform" rating, highlighting its leading profitability in the mining sector and upcoming production increases from key coal mines [8] - Guoxin Securities maintains an "Outperform" rating for China Oriental Education (00667.HK), noting a recovery in professional enrollment and an increase in net profit margin to 19.0% [9] - Guotou Securities maintains an "Accumulate" rating for Yum China (09987.HK), projecting a 3% same-store sales growth in Q4 2025 and plans for significant shareholder returns starting in 2027 [10]

Core Insights - Wuxi Heyou Biotechnology Co., Ltd. has completed a Pre-A round financing of several tens of millions of RMB [1] - The financing was led by Guolian Investment and Wuxi Xidong Industrial Investment Center, aimed at upgrading GMP-level products and accelerating global business expansion [1] - The company is entering a new phase of rapid development, focusing on enhancing product quality and capacity while strengthening its core advantages in domestic substitution [1] Financing Details - The financing amount is in the range of several tens of millions of RMB [1] - Investors include Guolian Investment's core market-oriented fund and Wuxi Xidong Industrial Investment Center [1] Business Strategy - Funds will be used to promote the iteration and upgrade of GMP-level products [1] - The company aims to deepen its international market presence by commercializing primary cells and related reagents and technical services globally [1] - There is a focus on improving the product matrix and reinforcing integrated solutions centered around primary cells [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 維 利 信™是一種同時靶向PD-L1與4-1BB的 雙 特 異 性 抗 體，為 針 對 肺 外 神 經 內 分泌癌的全球首款達到註冊臨床階段的靶向4-1BB受 體 的 療 法。於 非 小 細 胞 肺 癌、小 細 胞 肺 癌 及 肺 外 神 經 內 分 泌 癌 這3種適應症的II期 或 註 冊 臨 床 試 驗 中， 維 利 信™展 現 出 同 類 第 一 或 同 類 最 佳 臨 床 活 性 潛 力。維 利 信™亦有望成為治療 晚 期 肺 外 神 經 內 分 泌 癌 的 首 款 獲 批 藥 物。憑 藉 我 們 自 主 研 發 並 具 有 知 識 產 ...